Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib with Daunorubicine and Cytarabine in CML Myeloid Acute Phase
NCT00219765Phase 2Terminated
- Sponsor
- CHU de Poitiers
- Start
- May 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of imatinib in chronic myeloid leukemia (CML) (4 arms), sponsored by CHU de Poitiers. Primary endpoints: Tolerability of imatinib in combination with daunorubicine and cytarabine, Effectiveness of imatinib in combination with daunorubicine and cytarabine and 1 more. Started May 2001; status: terminated.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00219765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00219765.